Spruce Biosciences, Inc. (SPRB)

Over the past six months, Spruce Biosciences' stock price has experienced significant volatility. The share price saw a substantial increase of 499.69% between September 15, 2025, and May 5, 2026, and has gained 934.7% over the past 12 months. In April 2026, the company announced a public offering of common stock and pre-funded warrants, aiming to raise approximately $60 million, which led to a stock price decrease of 26.05%. In March 2026, the company reported its full-year 2025 financial results and provided corporate updates, including completing positive Type B FDA meetings for TA-ERT and securing a loan facility. In May 2026, Spruce Biosciences appointed a Vice President of Market Access and a Vice President of Commercial Operations. In October 2025, TA-ERT received FDA Breakthrough Therapy Designation. In March 2026, Spruce Biosciences terminated its collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. for tildacerfont in Japan.

The demand for Spruce Biosciences' products is not typically subject to seasonal fluctuations. Demand is driven by the prevalence of the diseases it targets, the successful development and regulatory approval of its therapies, and their subsequent commercialization and adoption by the medical community. The unmet medical need for these conditions suggests a consistent demand once effective treatments are available.

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare neurological and endocrine disorders with unmet medical needs. Their lead product candidate is tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB), which has received FDA Breakthrough Therapy Designation. They are also developing tildacerfont, an oral small-molecule antagonist of the CRF1 receptor, previously studied for major depressive disorder (MDD) and congenital adrenal hyperplasia (CAH).

Spruce Biosciences, Inc. is headquartered in South San Francisco, California, United States. Its focus on U.S. FDA designations and clinical trials suggests a primary operational and commercial focus within the United States for its lead programs.

Spruce Biosciences' brand reputation has been positively influenced by clinical advancements and regulatory milestones, such as the FDA's Breakthrough Therapy Designation for TA-ERT. Positive clinical data for TA-ERT has also contributed to a strong scientific and clinical reputation. Analyst consensus rates SPRB stock as a "Strong Buy" or "Moderate Buy". However, competition for tildacerfont and the recent public offerings have presented minor reputational challenges.

Spruce Biosciences, Inc. has a significant institutional ownership presence. As of May 4, 2026, 35 institutional owners and shareholders held a total of 727,601 shares. Major institutional shareholders include Ikarian Capital, LLC, Squadron Capital Management LLC, Citadel Advisors LLC, Wellington Management Group LLP, ADAR1 Capital Management, LLC, Alyeska Investment Group, L.P., Boothbay Fund Management, Llc, Balyasny Asset Management Llc, and Schonfeld Strategic Advisors LLC. Institutions hold approximately 91.71% of the stock, while individual insiders hold about 3.66%.